Endologix to Present at Two Upcoming Conferences

IRVINE, Calif., Nov. 8, 2011 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of minimally invasive treatments for aortic disorders, announced today that John McDermott, President and Chief Executive Officer, is scheduled to present at two upcoming investor conferences. The first presentation will be at the Stephens Fall Investment Conference in New York.

**Event:** Stephens Fall Investment Conference  
**Date:** Tuesday, November 15, 2011  
**Time:** 11:30 a.m. ET

The second presentation will be at the Lazard Capital Markets 8th Annual Healthcare Conference in New York.

**Event:** Lazard Capital Markets 8th Annual Healthcare Conference  
**Date:** Wednesday, November 16, 2011  
**Time:** 11:00 a.m. ET

An audio webcast of the Company’s presentations will be available by visiting the investor relations section of Endologix’s website at www.endologix.com. A replay of the presentations will be available for 30 days.

About Endologix, Inc.

Endologix, Inc. develops and manufactures minimally invasive treatments for aortic disorders. The Company's focus is endovascular stent grafts for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 75%, making it a leading cause of death in the U.S. Additional information can be found on Endologix's website at www.endologix.com.

CONTACT: COMPANY CONTACT:

Endologix, Inc.  
John McDermott, CEO  
(949) 595-7200  
www.endologix.com

INVESTOR CONTACTS:

The Ruth Group  
Nick Laudico  
(646) 536-7030  
Zack Kubow  
(646) 536-7020